The effect of autologous platelet-rich plasma local injection in facial rejuvenation

The safety and efficacy of autologous platelet-rich plasma local injection in facial rejuvenation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043437

Enrollment

Unknown

Registered

2021-02-17

Start date

2021-02-17

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial aging

Interventions

treatment group:autologous platelet-rich plasma local injection

control group:Regular Facial Care

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 40 and 70 years; (2) Skin Fitzpatrick type III or IV; (3) Have the need and willingness for facial rejuvenation, sign the informed consent of clinical trial voluntarily, and actively cooperate with treatment and follow visitors; (4) There is no deformity or scar on the face, and the aging degree on both sides of the face is the same; (5) No skin system diseases; (6) The ongoing treatment of the study subjects has no effect on this study.

Exclusion criteria

Exclusion criteria: (1) Have received facial surgery (such as Botox injection, subcutaneous filling, chemical stripping, electro-optic therapy, etc.) within 6 months prior to the date of operation; (2) There were herpes simplex virus infection, facial eczema, facial trauma, facial infection, facial neuritis and trigeminal neuralgia on the face during the trial; (3) Ultraviolet light sensitivity and scar constitution; (4) Pregnant or lactating women, women who plan to become pregnant during the study period; (5) Coagulation dysfunction; (6) Autoimmune diseases such as: Hashimoto's disease, rheumatoid arthritis; (7) Patients with severe organic diseases, such as coronary heart disease, hypertension, diabetes, pulmonary dysfunction and other unstable disease control; (8) Malignant tumor; (9) People suffering from acute or chronic infectious diseases, mental diseases and mental disorders.

Design outcomes

Primary

Measure	Time frame
Facial VISIA test;	—

Secondary

Measure	Time frame
Anterior and lateral high resolution facial photography;Facial four-dimensional color ultrasound;Skin spectrophotometer test;facial winkle scale;wrinkle severity rating scale;glabellar line severity score;Face -Q Appearance Assessment Scale;Face -Q Quality of Life Scale;Subjective satisfaction with treatment;Self-assessment Questionnaire;	—

Countries

China

Contacts

Public ContactPei Bin

Xiangyang No.1 People's Hospital, Affiliated Hospital of Hubei University of Medicine

binpei@hbmu.edu.cn+86 18995678520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026